Semaglutide may protect against psychiatric disorders independent of weight loss

New research indicates that higher doses of the medication semaglutide may be linked to a reduced risk of certain mental health and neurological conditions, even when taking into account weight loss. Semaglutide is a GLP-1 receptor agonist, originally developed for managing blood sugar levels in people with type 2 diabetes. The drug works by mimicking a natural hormone and binding to GLP-1 receptors on cells, influencing various bodily functions.

The study, conducted by Karthik Murugadoss and Venky Soundararajan of nference, examined the medical histories of thousands of patients to explore whether semaglutide's cognitive and mental health effects could be independent of weight loss. The researchers analyzed patient data from a large database of electronic health records and found that patients taking semaglutide had lower rates of new neuropsychiatric diagnoses compared to those taking metformin, a common diabetes medication.

Specifically, semaglutide users had a 29% lower relative risk of developing substance-related disorders and an 18% lower relative risk of mood disorders during the follow-up period. However, the researchers noted that this protective effect was not consistent across all neurological outcomes, such as dementia or degenerative central nervous system diseases, which did not show significant differences between semaglutide dose groups.

Furthermore, the amount of weight lost while taking semaglutide did not correlate with the patient's risk of developing neurological or psychiatric conditions. This suggests that the drug's effects on the brain may be driven by the medication itself, rather than simply the result of weight loss. The study emphasizes the need for further research to determine how weight changes alone relate to these outcomes and to investigate personalized precision medicine approaches for GLP-1 drugs.